Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUME-Colon 2: Nintedanib +/- Capecitabine in Refractory mCRC
NCT02780700Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2016
- Primary completion
- Sep 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nintedanib in colorectal cancer (CRC), sponsored by Boehringer Ingelheim. Started Jul 2016; status: terminated.
02
Drugs
nintedanib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02780700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02780700.